Navigation Links
ABACHEM: Reliable Development and Manufacturing Service Provider

SHANGHAI, May 9, 2013 /PRNewswire/ -- ABACHEM is a public listed company in China, specializing in contract manufacturing to the pharmaceutical, biotechnological and agrochemical industries. Offering a broad spectrum of services for the production of fine chemicals, advanced intermediates and active pharmaceutical ingredients, we have successfully collaborated and partnered with major pharmaceutical and agrochemical companies globally. ABACHEM has also become a reliable development and manufacturing service provider and meets clients' outsourcing needs by offering cost-effective and time-efficient services and products.

Our R&D department has over 80 scientists with solid industrial experience, providing process research and development services including process selection, optimization, and verification as well as reference standard and impurity preparations. Our laboratory is fully-equipped with modern analytical instruments such as NMR, HPLC, UPLC, LC-MS and GC-MS to ensure that all projects are delivered with accuracy and a high degree of purity. DSC and ARSST are applied to every project in our lab to provide a process safety and hazard assessment. Our four kilo-labs ensure that all kilo-projects are delivered on time. An isolated and state-of-the-art kilo-lab was recently built and dedicated to cGMP projects.

ABACHEM promotes innovation and is open-minded to new ideas and technologies. For example, we recognize that heterocyclic chemistry and asymmetric synthesis are the two most complex and intriguing branches of organic chemistry. The development of technologies and processes for heterocyclic and asymmetric synthesis have been areas of long-term focus for the company. Heterocycles manufactured based on processes developed in-house, such as pyrazoles, triazoles, aza-indoles and unnatural amino acids, are some of the highlights. For chiral technology, besides the traditional asymmetric synthesis, we have recently enhanced our capability by establishing a biocatalysis group.

ABACHEM has tremendous manufacturing capability and capacity. Five of our multi-functional pilot plants ensure a smooth tech-transfer from lab to commercial scale manufacturing. In addition, through years of CMO business, the company has accumulated invaluable knowledge and experience in bulk hazardous material sourcing and handling as well as regulatory filing including the latest New Chemicals Substance filing. We also have had a good track record of persistent improvement of cost structure for our clients' commercial products.

ABACHEM is continuously and actively improving its capabilities and capacity through new technologies & engineering as well as expansions for our core CMO services. We have recently expanded our hydrogenation capacity significantly by the installation of an additional eighteen hydrogenation reactors ranging from 1000 to 5000 L with two 1000L Hastelloy reactors to provide excellent material compatibility.


Founded in 2003, ABACHEM has developed into a public company with about 400 employees and over 1.2 million square feet of laboratory and manufacturing space. Currently, the company is headquartered in Shanghai with a R&D center in Zhangjiang Hi-Tech Park of Shanghai and three manufacturing facilities in Jiangsu province which are all within driving distance to Shanghai. 


Jane Wang

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Defeat Diabetes Foundation Teams with CoreMedica Laboratories to Provide Affordable and Reliable A1C Testing for Diabetics
2. Varian Medical Systems to Showcase Fast, Reliable, Wireless X-ray Image Detectors at the ECR Annual Meeting in Vienna Next Week
3. Fuisz Pharma Announces Patent Allowance For New Tablet And Caplet Shapes That Promote Rapid, Reliable Esophageal Transit
4. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
5. Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
6. Tribogenics Expands X-Ray Development Team With Key Hires
7. FEEL Golf Co., Inc. Signs EMR Software Development Agreement with ScheduleMorePatients LLC
8. Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
9. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
10. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
11. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... People across ... in Genome magazine’s Code Talker Award, an essay contest in which patients and their ... award to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):